Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1925 of 2026 entries
View as:

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01447446 Org: User:
Start: 09/30/11 End: 07/31/15 Due: 07/31/16

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01107418 Org: User:
Start: 05/31/10 End: 02/28/13 Due: 02/28/14

A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash

Phase: N/A Priority: Normal
NCT ID: NCT00642473 Org: User:
Start: 02/29/08 End: 03/31/09 Due: 03/31/10

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)

Phase: N/A Priority: Normal
NCT ID: NCT05494619 Org: User:
Start: 11/30/22 End: 09/30/26 Due: 09/30/27

A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00121836 Org: User:
Start: 06/30/05 End: 12/31/08 Due: 12/31/09

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)

Phase: N/A Priority: Normal
NCT ID: NCT01235559 Org: User:
Start: 12/31/10 End: 03/31/15 Due: 03/31/16

A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.

Phase: N/A Priority: Normal
NCT ID: NCT00623597 Org: User:
Start: 06/30/08 End: 03/31/10 Due: 03/31/11

An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)

Phase: N/A Priority: Normal
NCT ID: NCT02305615 Org: User:
Start: 01/13/15 End: 12/29/17 Due: 12/29/18

To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02846428 Org: User:
Start: 03/31/04 End: 12/31/11 Due: 12/31/12

A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03182504 Org: User:
Start: 06/15/17 End: 08/10/17 Due: 08/10/18

Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03153163 Org: User:
Start: 06/20/17 End: 09/27/18 Due: 09/27/19

An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants

Phase: N/A Priority: Normal
NCT ID: NCT02535026 Org: User:
Start: 07/31/11 End: 12/31/13 Due: 12/31/14

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03817853 Org: User:
Start: 02/26/19 End: 01/25/23 Due: 01/25/24

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT04431726 Org: User:
Start: 02/04/21 End: 05/18/30 Due: 05/18/31

A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

Phase: N/A Priority: Normal
NCT ID: NCT01922037 Org: User:
Start: 06/19/13 End: 03/31/16 Due: 03/31/17

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT02596971 Org: User:
Start: 12/22/15 End: 05/08/20 Due: 05/08/21

A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT00002190 Org: User:
Start: - End: - Due: -

A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01815827 Org: User:
Start: 06/30/13 End: 02/28/14 Due: 02/28/15

A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00502671 Org: User:
Start: 07/31/07 End: 03/31/12 Due: 03/31/13

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)

Phase: N/A Priority: Normal
NCT ID: NCT01702558 Org: User:
Start: 12/03/12 End: 05/31/17 Due: 05/31/18

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02324257 Org: User:
Start: 12/30/14 End: 09/03/19 Due: 09/03/20

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT02247531 Org: User:
Start: 10/06/14 End: 01/23/18 Due: 01/23/19

Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants

Phase: N/A Priority: Normal
NCT ID: NCT03959332 Org: User:
Start: 06/19/19 End: 07/11/19 Due: 07/11/20

A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01675427 Org: User:
Start: 08/31/11 End: 10/31/13 Due: 10/31/14

A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00700570 Org: User:
Start: 08/31/08 End: 11/30/11 Due: 11/30/12